Can-Fite BioPharma Posts Positive Phase 2a Signal for Namodenoson in Pancreatic Cancer
at www.tipranks.com (Tue, 2-Jun 7:33 AM)
Can-Fite’s Phase 2a Pancreatic Cancer Data Shows 35% of Patients Remain on Namodenoson Therapy, One for Over 16 Months
Market Chameleon (Thu, 30-Apr 10:31 AM)
Can-Fite’s Namodenoson Passes Key Safety Mark in Pancreatic Cancer Study, Setting Stage for Advanced Trials
Market Chameleon (Wed, 4-Mar 7:31 AM)
